Adding Neoadjuvant and Adjuvant Pembrolizumab to Standard Care Significantly Improves EFS Among Patients with Locally Advanced HNSCC By Ogkologos - July 7, 2025 624 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the KEYNOTE-689 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Patient Guide on Immunotherapy Side Effects and Their Management Now Available... April 29, 2026 10 Ways You Can Nurture A More Sustainable Garden June 18, 2021 Why haven’t we cured cancer? June 20, 2022 Approval of Elahere Expands Treatment Options for Some Advanced Ovarian Cancers April 24, 2024 Load more HOT NEWS Spotlight On: Exercise Physiologists in Cancer Care Boy Battling Cancer Becomes Honorary Police Officer, Sworn In To 45... Sotorasib Shows Increase in PFS and a More Favourable Safety Compared... ESMO 2022: New Research in Treating Gastrointestinal and Genitourinary Cancers
